<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pmj</journal-id><journal-title-group><journal-title xml:lang="ru">Тихоокеанский медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Pacific Medical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1609-1175</issn><publisher><publisher-name>TGMU</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17238/PmJ1609-1175.2017.2.50-52</article-id><article-id custom-type="elpub" pub-id-type="custom">pmj-139</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCHES</subject></subj-group></article-categories><title-group><article-title>Динамика состояния почек при назначении диклофенака и целекоксиба у больных оксалатной нефропатией</article-title><trans-title-group xml:lang="en"><trans-title>Condition of kidneys after Diclofenac and Celecoxib in patients with oxalate nephropathy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гельмутдинов</surname><given-names>Д. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Gelmutdinov</surname><given-names>D. D.</given-names></name></name-alternatives><email xlink:type="simple">nauca@fesmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воронина</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Voronina</surname><given-names>N. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Дальневосточный государственный медицинский университет; 7-й военный госпиталь внутренних войск МВД России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Far Eastern State Medical University; Military Hospital of Internal Troops of the Ministry for Internal Affairs</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Дальневосточный государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Far Eastern State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>28</day><month>06</month><year>2017</year></pub-date><volume>0</volume><issue>2</issue><fpage>50</fpage><lpage>52</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гельмутдинов Д.Д., Воронина Н.В., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Гельмутдинов Д.Д., Воронина Н.В.</copyright-holder><copyright-holder xml:lang="en">Gelmutdinov D.D., Voronina N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.tmj-vgmu.ru/jour/article/view/139">https://www.tmj-vgmu.ru/jour/article/view/139</self-uri><abstract><p>Изучали динамику функции почек и мочевого синдрома при применении курсовых доз диклофенака (3000 мг) и целекоксиба (6000 мг) у 51 женщины 45-60 лет, страдавшей оксалатной нефропатией с 1-2 стадией хронической болезни почек и первичным гоноартрозом. Целекоксиб продемонстрировал меньшую нефротоксичность, чем диклофенак. Последний вызывал обострение нефропатии, усиление оксалатно-кальциевой кристаллурии, появление микрогематурии и протеи-нурии. Целекоксиб приводил только к снижению скорости клубочковой фильтрации, не вызывая преобразований мочевого осадка. Изменения функции почек и мочевого осадка при приеме обоих препаратов были преходящими.</p></abstract><trans-abstract xml:lang="en"><p>Objective. Studied kidney functiona and urinary syndrome after using Diclofenac and Celecoxib in patients with oxalate nephropathy with primary gonarthrosis. Methods. We examined 51 women 45-60 years old, who suffered from oxalate nephropathy for more than 20 years with chronic kidney disease 1-2 stage with a glomerular filtration rate (GFR) of not less than 60 ml/min. Patients of the 1st group (22 people) took diclofenac sodium (course dose of 3000 mg) for a month, patients of the 2nd group (29 people) took celecoxib (course dose 6000 mg). Assessed GFR in dynamics, uric acid clearance and urinary syndrome (before treatment, on the 30th day of treatment, and a month after the drugs dechallenge). Results. By the 30th day of treatment with diclofenac, nephrotoxic effects were observed, characterized by a statistically significant decrease in GFR (from 89.0±9.1 to 57.5±2.9 ml/min) and uric acid clearance (from 5.2±9.1 to 4.1±0.4 ml/min). Microscopy of urine sediment showed an increase in aggregation of calcium oxalates, the appearance of microhematuria and proteinuria. Celecoxib by this time led to a moderate decrease in GFR (from 85.5±8.2 to 61.2±9.3 ml/min), but did not cause changes in the clearance of uric acid and urinary sediment. A month after the drugs dechallenge, all the indicators returned to their original level. Conclusions. Celecoxib demonstrated less nephrotoxicity than diclofenac. The latter caused an exacerbation of nephropathy, an increase in oxalate-calcium crystalluria, the appearance of microhematuria and proteinuria. Celecoxib only reduced the rate of glomerular filtration, without causing changes in urinary sediment.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>нестероидные противовоспалительные препараты</kwd><kwd>нефротоксичность</kwd><kwd>скорость клубочковой филтрации</kwd><kwd>мочевой осадок</kwd></kwd-group><kwd-group xml:lang="en"><kwd>non-steroid anti-inflammatory drugs</kwd><kwd>nephrotoxicity</kwd><kwd>glomerular filtration rate</kwd><kwd>urinary sediment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Андросова С.О., Фомин В.В., Шилов Е.М. Тубулоинтерстициальный нефрит // Нефрология: национальное руководство. М.: ГЭОТАР-Медиа, 2009. С. 403-411.</mixed-citation><mixed-citation xml:lang="en">Андросова С.О., Фомин В.В., Шилов Е.М. Тубулоинтерстициальный нефрит // Нефрология: национальное руководство. М.: ГЭОТАР-Медиа, 2009. С. 403-411.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Батюшин М.М., Терентьев В.П., Дмитриева О.В., Повилай-те П.Е. Хроническая болезнь почек: место нестероидных противовоспалительных препаратов. Элиста: Джангар, 2009. 128 с.</mixed-citation><mixed-citation xml:lang="en">Батюшин М.М., Терентьев В.П., Дмитриева О.В., Повилай-те П.Е. Хроническая болезнь почек: место нестероидных противовоспалительных препаратов. Элиста: Джангар, 2009. 128 с.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Воронина Н.В., Грибовская Н.В., Евсеев А.Н. Оксалатная нефропатия: клинико-морфологические исследования. Хабаровск: Изд-во ДВГМУ 2014. 136 с.</mixed-citation><mixed-citation xml:lang="en">Воронина Н.В., Грибовская Н.В., Евсеев А.Н. Оксалатная нефропатия: клинико-морфологические исследования. Хабаровск: Изд-во ДВГМУ 2014. 136 с.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Воронина Н.В., Слуцкая Н.П., Маркина О.И., Ковальская Л.П. [и др.]. Особенности лечения остеоартроза коленных суставов у больных оксалатной нефропатией // Терапевтический архив. 2015. № 4. С. 62-68.</mixed-citation><mixed-citation xml:lang="en">Воронина Н.В., Слуцкая Н.П., Маркина О.И., Ковальская Л.П. [и др.]. Особенности лечения остеоартроза коленных суставов у больных оксалатной нефропатией // Терапевтический архив. 2015. № 4. С. 62-68.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. [и др.]. Применение нестероидных противовоспалительных препаратов: клинические рекомендации. М.: ИМА-ПРЕСС. 2009. 168 с.</mixed-citation><mixed-citation xml:lang="en">Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. [и др.]. Применение нестероидных противовоспалительных препаратов: клинические рекомендации. М.: ИМА-ПРЕСС. 2009. 168 с.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Atmansori М., Kovithavongs Т., Oami M.U. Cyclooxygenase-2 inhibitor-associated minimal-change disease // Clin. Nephrol. 2005. Vol. 63, No. 5. Р 166.</mixed-citation><mixed-citation xml:lang="en">Atmansori М., Kovithavongs Т., Oami M.U. Cyclooxygenase-2 inhibitor-associated minimal-change disease // Clin. Nephrol. 2005. Vol. 63, No. 5. Р 166.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Breyer M.D., Hao C., Qi Z. Cyclooxygenase-2 selective inhibitors and the kidney // Curr. Opin. Crit. Care. 2001. Vol. 7, No. 6. Р. 393-400.</mixed-citation><mixed-citation xml:lang="en">Breyer M.D., Hao C., Qi Z. Cyclooxygenase-2 selective inhibitors and the kidney // Curr. Opin. Crit. Care. 2001. Vol. 7, No. 6. Р. 393-400.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ibanez L., Morlans M., Vidal X. [et al.]. Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renal disease // Kidney International. 2005. Vol. 67. Р. 2393-2398.</mixed-citation><mixed-citation xml:lang="en">Ibanez L., Morlans M., Vidal X. [et al.]. Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renal disease // Kidney International. 2005. Vol. 67. Р. 2393-2398.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Galesic K., Moivvic-Vergles J., Jelakovic B. Nonsteroidal antirheumatics and the kidney // Reumatizam. 2005. Vol. 52, No. 2. Р. 61-66.</mixed-citation><mixed-citation xml:lang="en">Galesic K., Moivvic-Vergles J., Jelakovic B. Nonsteroidal antirheumatics and the kidney // Reumatizam. 2005. Vol. 52, No. 2. Р. 61-66.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Harris R.C. Cyclooxygenase-2 in the kidney // J. Am. Soc. Nephrol. 2000. Vol. 11. Р 2387-2394.</mixed-citation><mixed-citation xml:lang="en">Harris R.C. Cyclooxygenase-2 in the kidney // J. Am. Soc. Nephrol. 2000. Vol. 11. Р 2387-2394.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Perazella M.A. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity // Am. J. Med. Sci. 2003. Vol. 325, No. 6. Р. 349-362.</mixed-citation><mixed-citation xml:lang="en">Perazella M.A. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity // Am. J. Med. Sci. 2003. Vol. 325, No. 6. Р. 349-362.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
